Intra-articular Versus Intravenous Dexmedetomidine in Arthroscopic Knee Surgeries Under Local Anesthesia

September 19, 2020 updated by: Mansoura University

Intra-articular Versus Intravenous Administration of Dexmedetomidine in Arthroscopic Knee Surgeries: A Prospective Randomized Study

The present study will be carried to evaluate the efficacy of intra-articular 0.5 bupivacaine with intra-articular or intravenous alpha-2agonist; Dexmedetomidine; for intraoperative anesthesia and postoperative analgesia after arthroscopic knee surgery.

Arthroscopic knee surgery is one of the most common minimally invasive orthopedic procedures in recent practice which is frequently performed as a day surgery procedures. It can be done under general, regional or local anesthesia (LA) with or without sedation. It is associated with varying amount of postoperative pain. Postoperative pain negatively influences patient's early ambulation, rehabilitation and psychology which consecutively prolonged the hospital stay.

Intra-articular administration of local anesthetic for knee arthroscopy is a well-documented procedure that offers many advantages over other anesthesia types. Many anesthesiologists are still trying to improve the technique of local anesthetic administration through using many combinations with LA solutions in order to administer safe anesthesia to those patients and to obtain a pain-free knee with good operating conditions.

Dexmedetomidine is a highly selective α2 adrenergic agonist. It has analgesic, sedative, anxiolytic, hypnotic, sympatholytic, antihypertensive properties with anesthetic sparing effects. It becomes an attractive alternative to the current opioids because it does not have a respiratory depressant or addictive effect.

Study Overview

Detailed Description

All patients were kept fasting after midnight and received midazolam 5 mg orally as premedication. All patients were premedicated with I.V. midazolam 0.03 mg/kg ten minutes before starting the operation. The anesthetic technique was standardized for all patients. All surgical procedures were performed by the same surgeon and consisted of arthroscopic removal of torn meniscus. Both intra-articular and intravenous solutions were prepared by an individual not involved in the study and the intra-articular drugs were injected by the surgeon (without knowing the contents). The anesthesiologist managing and monitoring the patient throughout the surgery provides IV drugs. No leg holder or tourniquet or surgical drain was used for any of the cases. After preparation and draping the patient's leg, patients were warned prior to each needle stick to decrease anxiety. All procedures were performed under complete aseptic conditions. Skin and subcutaneous tissues at each arthroscopic portal site were anesthetized with LA consisting of injection of a mixture of 2% lidocaine 5 mL with 1:200,000 epinephrine.

Care should be taken to avoid infiltration of the fat pad. It is a relatively aneural structure; as, too much local infiltration allows it to bulge out into the joint during the surgery. Flexion and extension of the knee joint several times help to spread of intra-articular solution and then waiting 20 minutes for anesthesia to take effect is helpful before the surgical incision.

The arthroscope was inserted into the knee, and inflow through the sheath was established. No pump was used for the saline inflow which was maintained through the arthroscope by the gravity. Gravity outflow drained through the superolateral portal. A separate egress cannula was used if indicated. The patient was encouraged to view the video monitor during the procedure. Constant verbal communication between the surgeon and the patient is important throughout the arthroscopic examination and surgery. This keeps the patient anxiety and muscle tension to the minimum which facilitates manipulation of the leg and thorough examination of the entire joint. Once finishing, instruments were removed and portals were closed with a 4-0 absorbable suture subcutaneously and steri-strips. A compression dressing was applied for three days to the knee.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • DK
      • Mansoura, DK, Egypt, 050
        • Mansoura University Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • American Society of Anesthesiologists physical status I or II
  • Patients scheduled for elective unilateral knee arthroscopy

Exclusion Criteria:

  • Refusal of local anesthesia
  • History of cardiovascular disease
  • History of cerebrovascular disease
  • History of respiratory diseases
  • History of impaired renal functions
  • History of impaired hepatic functions
  • Pregnancy
  • Allergy to the study drugs
  • Uncontrolled diabetes
  • Coagulopathies
  • Hypertension treated with α methyldopa, clonidine or β adrenergic blockers
  • Patients receiving chronic pain treatment
  • Patients receiving psychoactive drugs
  • Patients receiving anticoagulant drugs
  • Prior ipsilateral knee surgery
  • Infection at site of injection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Intra-articular dexmedetomidine
Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
PLACEBO_COMPARATOR: Intravenous dexmedetomidine
patients will be subjected for elective knee arthroscopy under local anesthesia (i.v. dexmedetomidine + Intra-articular bupivacaine).
Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain scores
Time Frame: for 24 hours starting immediately before performing the procedure
Pain will be assessed using 10 cm visual analogue scale (VAS)
for 24 hours starting immediately before performing the procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart rate
Time Frame: starting immediately before performing the procedure
starting immediately before performing the procedure
Blood pressure
Time Frame: starting immediately before performing the procedure
Changes in systolic and mean blood pressure
starting immediately before performing the procedure
Oxygen saturation
Time Frame: starting immediately before performing the procedure
Changes in peripheral oxygen saturation
starting immediately before performing the procedure
Respiratory rate
Time Frame: starting immediately before performing the procedure
Changes in respiratory rates will be recorded
starting immediately before performing the procedure
Level of sedation
Time Frame: For 24 hours after performing the injection
will be evaluated using the following scale: (5= awake/alert to 0= asleep/unarousable )
For 24 hours after performing the injection
Patient Satisfaction Score
Time Frame: For 24 hours after performing the procedure

will be assessed using the following scale: 5= very satisfied, 4= satisfied, 3 = neutral, 2 = dissatisfied,

1 = very dissatisfied

For 24 hours after performing the procedure
Time to first postoperative analgesic requirement
Time Frame: For 24 hours after performing the injection
This will be recorded as the time to first postoperative analgesic requirement
For 24 hours after performing the injection
Intraoperative and postoperative side effects
Time Frame: For 24 hours after performing the injection
These include nausea, vomiting, hypotension, bradycardia, respiratory depression, Hypertension
For 24 hours after performing the injection
Time to mobilization out of bed
Time Frame: For 48 hours after performing the procedure
will be recorded in minutes from skin closure
For 48 hours after performing the procedure
Post-anesthesia care unit (PACU) length of stay
Time Frame: For 4 hours after surgery
will be recorded from time between transfer from the operating room to PACU and discharge
For 4 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tarek H Ramadan, MD, Lecturer of anesthesia and surgical intensive care
  • Study Director: Reem A AbdelRaouf, MD, Lecturer of anesthesia and surgical intensive care

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 1, 2015

Primary Completion (ACTUAL)

April 1, 2016

Study Completion (ACTUAL)

May 30, 2016

Study Registration Dates

First Submitted

February 11, 2016

First Submitted That Met QC Criteria

April 6, 2016

First Posted (ESTIMATE)

April 7, 2016

Study Record Updates

Last Update Posted (ACTUAL)

September 22, 2020

Last Update Submitted That Met QC Criteria

September 19, 2020

Last Verified

September 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Arthroscopy

Clinical Trials on Intra-articular dexmedetomidine

3
Subscribe